Zai Lab Ltd (ZLAB) Stock Price & Analysis
Zai Lab Ltd (ZLAB) fell 2.85% to USD 26.23 as of September 8, 2026 at 04:59 UTC, according to Nexqual real-time market data.
ZLAB last closed at USD 27; the session ranged USD 25.48–26.49 on volume of 812,771 shares. Market capitalization is $2.94B, with a 52-week range of USD 15.96–34.72 (NGM). Source: Nexqual, September 8, 2026 at 04:59 UTC.
Key Statistics (as of September 8, 2026 at 04:59 UTC)
| Price | USD 26.23 |
|---|---|
| Change | ▼ 2.85% (down) |
| Previous Close | USD 27 |
| Open | USD 26.48 |
| Day Range | USD 25.48 – 26.49 |
| 52-Week Range | USD 15.96 – 34.72 |
| Volume | 812,771 shares |
| Market Cap | $2.94B |
| Exchange | NGM |
Technical Analysis (ZLAB)
Nexqual's technical model rates ZLAB "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 04:59 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 59.43 (neutral) |
| vs SMA50 | Above (USD 22.05) |
| MACD | 1.3 (positive) |
Analyst Ratings (ZLAB)
Wall Street analysts rate ZLAB "Strong Buy" based on 12 analysts, with a mean price target of USD 33.14 (range USD 24.25–50), per Nexqual as of September 8, 2026 at 04:59 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 33.14 |
| High Target | USD 50 |
| Low Target | USD 24.25 |
| Buy / Hold / Sell | 11 / 1 / 0 |
Earnings (ZLAB)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.56 |
| Revenue Estimate | $108.82M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.46 vs est -0.68 ▲ beat |
| 2026-03-31 | USD -0.46 vs est -0.53 ▲ beat |
| 2025-12-31 | USD -0.46 vs est -0.42 ▼ miss |
| 2025-09-30 | USD -0.33 vs est -0.29 ▼ miss |
Source: Nexqual, September 8, 2026 at 04:59 UTC.
Financials & Fundamentals (ZLAB)
| Total Revenue | $449.61M |
|---|---|
| Revenue Growth (YoY) | -3.30% |
| Gross Margin | +3.78% |
| Operating Margin | -71.95% |
| Profit Margin | -41.86% |
| ROE | -26.91% |
| Debt / Equity | 41.94 |
| Current Ratio | 2.13 |
| Total Cash | $617.52M |
| Total Debt | $254.58M |
| Free Cash Flow | $-83.96M |
Source: Nexqual, September 8, 2026 at 04:59 UTC.
Financial Health Score (ZLAB)
Nexqual rates Zai Lab Ltd's overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 04:59 UTC.
| Growth | Strong — Revenue +15% YoY (annual) |
|---|---|
| Profitability | Critical — Gross margin 4%, operating -72% |
| Balance Sheet | Strong — $618M cash vs $255M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$84M, burning cash |
| Efficiency | Critical — ROE -27%, ROA -14.7% |
Ownership (ZLAB)
| Insider Ownership | +2.15% |
|---|---|
| Institutional Ownership | +38.47% |
| Shares Outstanding | 112.27M |
| Float | 97.11M |
| Short % of Float | +6.79% |
Source: Nexqual, September 8, 2026 at 04:59 UTC.
Leadership (ZLAB)
Zai Lab Ltd is led by Ying Du (age 59), Founder, Chairperson & CEO, per Nexqual as of September 8, 2026 at 04:59 UTC.
| Founder, Chairperson & CEO | Ying Du (age 59) |
|---|---|
| President and Head of Global Research & Development | Rafael G. Amado (age 61) |
| Chief Financial Officer | Yajing Chen (age 57) |
| Chief Operating Officer of Global R & D | James Yan DABT (age 61) |
Major Backers & Investors (ZLAB)
Notable institutional backers of Zai Lab Ltd include RTW Investments LP, TCG Crossover Management, LLC, RA Capital Management, L.P., according to Nexqual as of September 8, 2026 at 04:59 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RTW Investments LP | 5.78% |
| TCG Crossover Management, LLC | 5.39% |
| RA Capital Management, L.P. | 5.05% |
| Adar1 Capital Management, LLC | 2.96% |
| FMR, LLC | 2.47% |
| Goldman Sachs | 2.03% |
| Woodline Partners LP | 1.94% |
| Frazier Life Sciences Management, L.P. | 1.67% |
Source: Nexqual, September 8, 2026 at 04:59 UTC.
From Zai Lab Ltd's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Intellectual Property Our commercial success depends, in part, on our ability to obtain and maintain proprietary protection for our know-how and innovation pertaining to our commercial products and product candidates as well as our core technologies; to operate without infringing, misappropriating, or otherwise violating the proprietary rights of others; and to prevent others from infringing, misappropriating, or otherwise violating our proprietary rights.
- We seek to protect our proprietary information, in part, by executing confidentiality agreements with our partners, collaborators, scientific advisors, employees, consultants, and other third parties.
- These confidentiality agreements are designed to protect our proprietary information and generally include clauses requiring assignment of inventions to us to grant us ownership of technologies that are developed through our relationship with the respective counterparty.
- Such agreements may not provide adequate protection of our proprietary information.
Partnerships
- In November 2024, we entered into a strategic collaboration with Pfizer that allows us to leverage the industry-leading commercialization infrastructure of Pfizer's affiliated companies in the anti-infective therapeutic area to support sales of XACDURO in mainland China.
- NovoCure (Tumor Treating Fields) In September 2018, we entered into a license and collaboration agreement with NovoCure, pursuant to which we obtained an exclusive license under certain patents and know-how of NovoCure to develop and commercialize any Tumor Treating Fields (OPTUNE) products in all human therapeutic and preventative uses in the field of oncology in Greater China.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HCM | HUTCHMED (China) Limited | USD 14.09 | ▲ 17.03% |
| LEGN | Legend Biotech Corporation | USD 21.52 | ▼ 1.69% |
| DNLI | Denali Therapeutics Inc. | USD 22.28 | ▼ 2.49% |
| GDS | GDS Holdings Limited | USD 31.37 | ▲ 1.78% |
| NBP | NovaBridge Biosciences | USD 1.8 | ▲ 0.56% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 04:59 UTC. This page is informational and not investment advice.